KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Guardant Health (GH) over the last 7 years, with Sep 2025 value amounting to $580.0 million.

  • Guardant Health's Cash & Equivalents fell 0.86% to $580.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $580.0 million, marking a year-over-year decrease of 0.86%. This contributed to the annual value of $525.5 million for FY2024, which is 53.64% down from last year.
  • According to the latest figures from Q3 2025, Guardant Health's Cash & Equivalents is $580.0 million, which was down 7.81% from $629.1 million recorded in Q2 2025.
  • Guardant Health's Cash & Equivalents' 5-year high stood at $1.1 billion during Q4 2023, with a 5-year trough of $141.6 million in Q4 2022.
  • For the 3-year period, Guardant Health's Cash & Equivalents averaged around $642.4 million, with its median value being $585.0 million (2024).
  • As far as peak fluctuations go, Guardant Health's Cash & Equivalents slumped by 80.98% in 2022, and later surged by 700.25% in 2023.
  • Over the past 5 years, Guardant Health's Cash & Equivalents (Quarterly) stood at $492.2 million in 2021, then tumbled by 71.22% to $141.6 million in 2022, then skyrocketed by 700.25% to $1.1 billion in 2023, then crashed by 53.64% to $525.5 million in 2024, then declined by 0.86% to $580.0 million in 2025.
  • Its Cash & Equivalents was $580.0 million in Q3 2025, compared to $629.1 million in Q2 2025 and $698.6 million in Q1 2025.